Service Ecosystem

Balb/C 3T3 neutral red uptakeAnalytical Method Development.

Bacterial mutation assay; Photogenotoxicity - Ames Test;

Impact on hERG potassium channel activity by patch-clamp technique.

Measure of ECG, primary (heart rate, blood pressure) and advanced (including stroke volume, cardiac output, total peripheral resistance and regional blood flows) hemodynamic parameters on anaesthetized dog, monkeys and rodents;

Effect on cardiovascular function in conscious dog, minipig and monkey using telemetry combined with assessment of effect on the autonomic nervous system (HFAM model) and modelization of hemodynamic effect (stroke volume, cardiac output, total peripheral resistance).

Test by direct or indirect contact in clone 929, Balb/C 3T3, V79.

Dose range finding study and repeated dose toxicity (up to 52 weeks). Administration routes: oral gavage, intravenous by bolus or continuous infusion (up to 4 weeks), subcutaneous, ocular and intramuscular.

Dose range finding study and repeated dose toxicity (up to 52 weeks). Administration routes: oral gavage, capsules, diet, intravenous by bolus or continuous infusion (up to 13 weeks), subcutaneous, dermal, ocular, intramuscular, intranasal and intraperitoneal (at an appropriate dose regimen).

Dose range finding study and repeated dose toxicity (up to 39 weeks). Administration routes: oral gavage, intravenous by bolus or continuous infusion (up to 8 weeks), subcutaneous, ocular and intramuscular.

Single dose and dose range finding and repeated dose toxicity (up to 52 weeks). Administration routes: oral, intravenous (up to 4 weeks), subcutaneous, intramuscular (up to 4  weeks) and intraperitoneal (at an appropriate dose regimen).

Dose range finding study and repeated dose toxicity (up to 39 weeks). Administration routes: oral gavage, capsules, intravenous, subcutaneous, dermal, ocular, intramuscular, intradermal and intra-articular (at an appropriate dose regimen).

Single dose and dose range finding and repeated dose toxicity (up to13 weeks). Administration routes: oral gavage, dermal, subcutaneous, intramuscular (up to 4 weeks), intra-articular, ocular and intravitreal (at an appropriate dose regimen).

Single dose and dose range finding and repeated dose toxicity (up to 52 weeks). Administration routes: oral gavage, diet, dermal, intravenous by bolus or continuous infusion (up to 13 weeks), subcutaneous, intramuscular (up to 4 weeks), intranasal, intratracheal, intraperitoneal (at an appropriate dose regimen), intradermal and intravesical.

Colony forming unit granulocyte/macrophage assay;

Red blood cell haemolysis test.

Cytotoxicity in primary rat hepatocytes;

HepG2 cell screening test.

Cytochrome p450, Glutathion S-transferase, γ-Glutamyl transpeptidase, Cytochrome oxidase, Adenosine triphosphatase, Glucose-6-phosphate dehydrogenase.

Mitochondrial Reductase Activity (MTT Staining) and Sulforhodamine B Uptake in several cancer cell lines.

(i) Evaluation of metabolism using liver metabolic fractions (S9, microsomes); evaluation of metabolism using hepatocytes; (ii) CYP induction in human hepatocytes and liver microsomes.

Cell proliferation and migration in primary normal human keratinocytes.

(i) Carcinogenicity study in rat or mouse following oral or subcutaneous administration (toxicokinetic can be included); (ii) Combined chronic toxicity-carcinogenicity study in rat following oral or subcutaneous administration (toxicokinetic can be included).

(i) Gene mutation in Chinese hamster V79 cells (HPRT); (ii) Mutation in L5178Y TK+/- mouse lymphoma cells (fluctuation method); (iii) in vitro chromosome aberrations in Chinese hamster cells (V79 CHO) and human lymphocytes; (iv) in vitro micronucleus test on human lymphocytes or Chinese hamster cells (V79 CHO).

(i) in vivo micronucleus test (single dose or multiple dose) in mouse and rat; (ii) in vivo chromosomal aberration test (single dose or multiple dose) in  rat; (iii) unscheduled DNA synthesis (UDS) in primary rat hepatocytes after in vivo treatment; (iv) in vivo comet assay in rat; (v) combined comet assay and micronucleus test after repeated dosing in rat

LLC-RK1 cell screening test.

Deep expertise in human recombinant proteins, notably GSCF, hGH and EPO (in vivo)

Analysis of several biological samples (plasma, urine, tissues, etc.) in different species (rat, mouse, rabbit, dog, minipig, marmoset) following drug administrations with all routes (intravenous, intraperitoneal, subcutaneous, oral).

Balb/C 3T3 cell phototoxicity assay (neutral red uptake).

(i) Palatability StudyIn rat and mouse following oral administration; (ii) Preliminary 4- and 13-week toxicity study in rat ore mouse following oral or subcutaneous administration.

Membrane barrier test method for skin corrosion (Corrositex®);

Human skin model test (Episkin™) Process Research & Development;

Human skin model test (Episkin™).

In vitro Skin Absorption (OECD 428).